[{"indications": "Indications\u00a0adjunct to statin in dyslipidaemia or\r\nused alone if statin not tolerated (see also lipid-regulating drugs)", "name": "NICOTINIC ACID With laropiprant", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.12 Lipid-regulating drugs", "Nicotinic acid group", "NICOTINIC ACID", "With laropiprant"], "cautions": "Cautions\u00a0unstable angina, acute myocardial infarction, diabetes\r\nmellitus, gout, history of peptic ulceration; interactions: Appendix 1 (nicotinic acid)", "side-effects": "Side-effects\u00a0diarrhoea, nausea, vomiting, abdominal pain, dyspepsia;\r\nflushing; pruritus, rash; less commonly tachycardia,\r\npalpitation, shortness of breath, peripheral oedema, headache, dizziness,\r\nincrease in uric acid, hypophosphataemia, prolonged prothrombin time,\r\nand reduced platelet count; rarely hypotension, syncope,\r\nrhinitis, insomnia, reduced glucose tolerance, myalgia, myopathy,\r\nmyasthenia; very rarely anorexia, rhabdomyolysis,\r\nvisual disturbance, and jaundice also reportedNote\u00a0Prostaglandin-mediated symptoms\r\n(such as flushing) can be reduced by low initial doses taken with\r\nmeals or, if patient taking aspirin, aspirin dose should be taken\r\n30 minutes before nicotinic acid", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/204110.htm", "doses": ["See under preparation", "Name[Tredaptive\u00ae (MSD)  ] Tablets, m/r, nicotinic acid 1\u00a0g,\r\nlaropiprant 20\u00a0mg, net price 28-tab pack = \u00a316.73; 56-tab pack = \u00a333.46. \r\n    Label:\r\n    21, 25Dose\u00a01 tablet once daily at night, increased after 4 weeks\r\nto 2 tablets once daily at night"], "pregnancy": "Pregnancy\u00a0no information available\u2014manufacturer advises avoid\r\nunless potential benefit outweighs risk"}, {"indications": "Indications\u00a0adjunct to statin in dyslipidaemia or\r\nused alone if statin not tolerated (see also lipid-regulating drugs)", "name": "NICOTINIC ACID", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.12 Lipid-regulating drugs", "Nicotinic acid group", "NICOTINIC ACID"], "cautions": "Cautions\u00a0unstable angina, acute myocardial infarction, diabetes\r\nmellitus, gout, history of peptic ulceration; interactions: Appendix 1 (nicotinic acid)", "side-effects": "Side-effects\u00a0diarrhoea, nausea, vomiting, abdominal pain, dyspepsia;\r\nflushing; pruritus, rash; less commonly tachycardia,\r\npalpitation, shortness of breath, peripheral oedema, headache, dizziness,\r\nincrease in uric acid, hypophosphataemia, prolonged prothrombin time,\r\nand reduced platelet count; rarely hypotension, syncope,\r\nrhinitis, insomnia, reduced glucose tolerance, myalgia, myopathy,\r\nmyasthenia; very rarely anorexia, rhabdomyolysis,\r\nvisual disturbance, and jaundice also reportedNote\u00a0Prostaglandin-mediated symptoms\r\n(such as flushing) can be reduced by low initial doses taken with\r\nmeals or, if patient taking aspirin, aspirin dose should be taken\r\n30 minutes before nicotinic acid", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/204109.htm", "doses": ["See under preparation"], "pregnancy": "Pregnancy\u00a0no information available\u2014manufacturer advises avoid\r\nunless potential benefit outweighs risk"}, {"indications": "Indications\u00a0adjunct to statin in dyslipidaemia or\r\nused alone if statin not tolerated (see also lipid-regulating drugs)", "name": "NICOTINIC ACID Modified release", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.12 Lipid-regulating drugs", "Nicotinic acid group", "NICOTINIC ACID", "Modified release"], "cautions": "Cautions\u00a0unstable angina, acute myocardial infarction, diabetes\r\nmellitus, gout, history of peptic ulceration; interactions: Appendix 1 (nicotinic acid)", "side-effects": "Side-effects\u00a0diarrhoea, nausea, vomiting, abdominal pain, dyspepsia;\r\nflushing; pruritus, rash; less commonly tachycardia,\r\npalpitation, shortness of breath, peripheral oedema, headache, dizziness,\r\nincrease in uric acid, hypophosphataemia, prolonged prothrombin time,\r\nand reduced platelet count; rarely hypotension, syncope,\r\nrhinitis, insomnia, reduced glucose tolerance, myalgia, myopathy,\r\nmyasthenia; very rarely anorexia, rhabdomyolysis,\r\nvisual disturbance, and jaundice also reportedNote\u00a0Prostaglandin-mediated symptoms\r\n(such as flushing) can be reduced by low initial doses taken with\r\nmeals or, if patient taking aspirin, aspirin dose should be taken\r\n30 minutes before nicotinic acid", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/128209.htm", "doses": ["See under preparation", "Name[Niaspan\u00ae ] Tablets, m/r, nicotinic acid 500\u00a0mg;\r\n750\u00a0mg; 1\u00a0gAvailable from \u2018special-order\u2019 manufacturers\r\nor specialist importing companies"], "pregnancy": "Pregnancy\u00a0no information available\u2014manufacturer advises avoid\r\nunless potential benefit outweighs risk"}]